Results 51 to 60 of about 479 (110)

A battery of tandem mass spectrometry assays with stable isotope-dilution for the quantification of 15 anti-tuberculosis drugs and two metabolites in patients with susceptible-, multidrug-resistant- and extensively drug-resistant tuberculosis.

, 2022
Anti-tuberculosis (antiTB) drugs are characterized by an important inter-interindividual pharmacokinetic variability poorly predictable from individual patients' characteristics.
André, P., Mazza-Stalder, J., Koehler, N., Lange, C., Decosterd, L.A., Sanchez Carballo, P.M., Cruchon, S., Briki, M., Mercier, T., Da Silva Pereira Clara, J.A., Choong, E., Desfontaine, V., Kajkus, A., Buclin, T., Burger, R., Suttels, V., Opota, O.   +16 more
core   +1 more source

Plasma concentrations of sutezolid (pink) and its major metabolite (yellow) at steady state (day 13–14) in patients treated with sutezolid 600 mg BID (left) or 1200 mg QD (right).

, 2014
Solid lines indicate medians; shading indicates 90% CI. Lower and upper dotted lines indicate median pre-treatment MIC values for parent and metabolite, respectively.
Amour Venter (551594), Darcy Paige (334958), Annette Silvia (334962), Yao Zhang (134381), Tong Zhu (8079), Paul Miller (71343), Rodney Dawson (101812), Jason Gobey (551595), Andreas H. Diacon (551597), Robert S. Wallis (286546), Sven O. Friedrich (551593), Craig Ellery (551596), Kathleen Eisenach (225003)   +12 more
core   +1 more source

Triclabendazole and sutezolid are not effective in vivo against Plasmodium berghei.

Drug repositioning has emerged as an attractive strategy to accelerate the development of new antimalarial therapies, particularly by evaluating compounds already used against pathologies co-endemic with malaria.
BRUNO PRADINES, JEROME DORMOI, REMY AMALVICT, LEO MILLOT   +3 more
core   +1 more source

Geometric mean pharmacokinetic parameters in patients of sutezolid and its major metabolite following dosing for 14 Days.

, 2014
CV = coefficient of variation.
Amour Venter (551594), Darcy Paige (334958), Annette Silvia (334962), Yao Zhang (134381), Tong Zhu (8079), Paul Miller (71343), Rodney Dawson (101812), Jason Gobey (551595), Andreas H. Diacon (551597), Robert S. Wallis (286546), Sven O. Friedrich (551593), Craig Ellery (551596), Kathleen Eisenach (225003)   +12 more
core   +1 more source

Treatment of Buruli ulcer: research, development, and repurposing of new therapeutics targeting Mycobacterium ulcerans [PDF]

Mycobacterium ulcerans é o agente patogénico responsável pela Úlcera de Buruli, uma doença infeciosa tropical negligenciada. A Organização Mundial da Saúde classifica a Úlcera de Buruli em diferentes estadios clínicos, desde pequenas lesões pré ...
Dominguez Enriquez, Juan Pablo
core   +1 more source

Side-by-Side Profiling of Oxazolidinones to Estimate the Therapeutic Window against Mycobacterial Infections. [PDF]

Antimicrob Agents Chemother, 2023
Negatu DA, Aragaw WW, Cangialosi J, Dartois V, Dick T.   +4 more
europepmc   +1 more source

Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis

, 2012
: Novel oral regimens composed of new drugs with potent activity against Mycobacterium tuberculosis and no cross-resistance with existing agents are needed to shorten and simplify treatment for both drug-susceptible and drug-resistant tuberculosis.
Williams, Kathy, Mdluli, Khisimuzi, Amoabeng, Opokua, Taylor, Dinesh, Peloquin, Charles A., Nuermberger, Eric L., Minkowski, Austin, Andries, Koen, Wallis, Robert S.   +8 more
core  

Bioluminescence for Assessing Drug Potency against Nonreplicating Mycobacterium tuberculosis

Targeting dormant Mycobacterium tuberculosis represents a challenge to antituberculosis drug discovery programs. We previously reported and validated the use of the streptomycin (STR)-dependent M.
Hartkoorn, Ruben C., Vocat, Anthony, Cole, Stewart T., Sala, Claudia, Lechartier, Benoit, Zhang, Ming, Dhar, Neeraj   +6 more
core   +1 more source

Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169)

The efficacy of the standardized four-drug regimen (comprising isoniazid, rifampin, pyrazinamide, and ethambutol) for the treatment of tuberculosis (TB) is menaced by the emergence of multidrug-resistant (MDR) and extensively drugresistant (XDR) strains ...
Vocat, Anthony, Blattes, Emilyne, Cole, Stewart T., Gillon, Jean-Yves, Lupien, Andreanne, Foo, Caroline Shi-Yan, Makarov, Vadim   +6 more
core   +1 more source

Antimicrobial Effect of Oxazolidinones and Its Synergistic Effect with Bedaquiline Against Mycobacterium abscessus Complex. [PDF]

Infect Drug Resist, 2023
Gao T, Yao C, Shang Y, Su R, Zhang X, Ren W, Li S, Shu W, Pang Y, Li Q.   +9 more
europepmc   +1 more source